Authors: T K Dutta S P Verma
Publish Date: 2013/02/23
Volume: 30, Issue: 2, Pages: 85-90
Abstract
In the United States the FDAapproved indications for recombinant factor VIIa is for bypassing inhibitors to factors VIII and IX in patients with hemophilia A and B respectively and for treatment of congenital factor VII deficiency In European countries rFVIIa is licensed for the above indications as well as for Glanzmann’s thrombasthenia In absence of highquality data favoring offlabel use of this agent and laboratory test to predict response to this agent and in view of high cost of rFVIIa offlabel use of recombinant factor VIIa should be restricted to only when hemorrhage has not responded to transfusion or other conventional therapy It appears two such conditions where recombinant factor VIIa may be beneficial are traumatic and postpartum hemorrhages
Keywords: